二甲雙胍已成為臨床治療2型糖尿病的一線口服降糖藥，最新研究表明二甲雙胍除了能通過改善胰島素抵抗、抑制肝臟糖異生等參與調(diào)節(jié)血糖水平外，還能明顯降低糖尿病患者中卵巢癌、肝癌、肺癌等多種癌癥的發(fā)生率、復(fù)發(fā)率和死亡率。綜述了二甲雙胍能通過激活A(yù)MPK信號(hào)通路、誘導(dǎo)細(xì)胞周期停滯及細(xì)胞凋亡、抑制血管生成、抑制膀胱癌干細(xì)胞增殖、增強(qiáng)化療藥物等對(duì)膀胱癌細(xì)胞的療效等多種分子機(jī)制產(chǎn)生抗膀胱癌的作用，展望了其成為新一代治療膀胱癌藥物的可能。

Currently, metformin has become a first-line oral hypoglycemic agent for the treatment of type 2 diabetes mellitus. The latest research shows that metformin can not only play a role in regulating blood glucose level by improving insulin resistance and inhibiting liver gluconeogenesis, but also significantly reduce the incidence, recurrence and mortality of many types of cancer, such as ovarian cancer, liver cancer, and lung cancer in diabetic patients. This paper summarizes that metformin can produce anti-bladder cancer effects by activating AMPK signaling pathway, inducing cell cycle arrest and apoptosis, inhibiting angiogenesis, inhibiting the proliferation of bladder cancer stem cells, and enhancing the efficacy of chemotherapy drugs on bladder cancer cells and provides the possibility of metformin as a new drugs for the treatment of bladder cancer.